Phase I studies of MK-4621, an oligonucleotide agonist of RIG-I, indicate that intratumoral injection of MK-4621/jetPEITM or combination of MK-4621 with pembrolizumab (MK-3475; anti-PD1 mAb) is well tolerated and capable of activating RIG-I pathway in cancer patients, while no clinical benefit has been shown [280]. Here, RIGI is linked to cancer.